RE: VPHM
14-Aug-2006
Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statem
Item 3.02. Unregistered Sales of Equity Securities
On August 11, 2006, ViroPharma Incorporated (the "Company") and Wyeth Pharmaceuticals, a division of Wyeth ("Wyeth") achieved a milestone set forth in the Stock Purchase Agreement dated December 9, 1999, as amended, between Wyeth and the Company (the "Agreement") related to the clinical development program with HCV-796, an investigational oral non nucleoside hepatitis C virus (HCV) polymerase inhibitor. As a result of achieving the milestone, on August 16, 2006, Wyeth will purchase 981,836 shares of ViroPharma common stock for a purchase price of $10,000,000. The price per share for the stock was based on a premium to a trailing average price.
